Skip to content

IN THE NEWS

Cardiac Science Receives Award for Global Excellence in ECG Monitoring from Frost and Sullivan

July 25, 2007


BOTHELL, WA –Cardiac Science Corporation, a global leader in advanced cardiac monitoring and defibrillation products, announced today that it has received Frost & Sullivan’s award for Global Excellence in ECG Monitoring, which recognizes its superior leadership and innovative vision in the cardiac monitoring marketplace.

Frost & Sullivan determines the Award recipient based on numerous factors, including the company’s business development, competitive strategy and leadership within the Frost & Sullivan ECG Monitoring Industry Research Group. 

Cardiac Science’s leadership in cardiac monitoring is the product of two of its predecessor companies, Quinton Cardiology Systems and Burdick Inc.  Quinton acquired Burdick in 2003 and Cardiac Science in September 2005.  Today, Cardiac Science is a global leader in the development, manufacture and marketing of non-invasive, diagnostic and therapeutic cardiology devices and services, including industry-leading electrocardiography devices marketed under the Burdick and Quinton brand names.

Burdick and Quinton brand ECGs offer hospitals and physicians a variety of solutions, including traditional and PC-based ECGs, for both acute and ambulatory care settings.  The Company’s current product line features innovations that are well known for ensuring timely, high-quality and accurate ECG results critical for patient care, including:

    • Leading-edge communications capabilities, including connectivity to leading electronic medical record (EMR) software and systems;
    • Comprehensive ECG data management, capturing patient reports from stress systems, Holter monitors and ECG devices;
    • An industry-leading interpretation algorithm that considers five clinically significant criteria.

“Our Burdick and Quinton brand devices have maintained the respect and loyalty of hospital and physician customers for decades,” said John Hinson, Cardiac Science president and CEO.  “We believe that this is due to our commitment to providing quality, innovation and superior service to physicians on the front-line of cardiac care, and setting the standard for clinical efficacy and ease-of-use. We are delighted that Frost & Sullivan has chosen to recognize our continued leadership and innovation in this marketplace.”  

This is the second time Cardiac Science has been recognized by Frost & Sullivan for its leadership in this market.  Frost & Sullivan awarded Quinton Cardiology Systems, one of Cardiac Science’s predecessor companies, its prestigious Growth Strategy Excellence Award in the global market for cardiovascular monitoring devices in March 2004. 

For more information on Frost & Sullivan’s Best Practices Awards, go to www.awards.frost.com.

About Cardiac Science

Cardiac Science, a wholly owned subsidiary of Opto Circuits (India) Ltd., develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, PC-based diagnostic workstations, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick®, HeartCentrix®, Powerheart®, and Quinton® brands, is headquartered in Bothell, Washington. With customers in almost 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

Forward-Looking Statements

This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation's future AED sales in Japan, expected shipments of backordered products in the fourth quarter of 2010, and expectations regarding the closing of the transaction with Opto Circuits. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results and performance may vary significantly from those expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks include those more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2009, as updated by subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

For updates and information on worldwide defibrillation and cardiac monitoring, find us on Facebook at http://facebook.com/cardiacscience, the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, and YouTube at http://budurl.com/CSonYT

For information, contact (media) Anastasia Mironova amironova@cardiacscience.com+1.425.402.2092 | (investors) ir@optoindia.com | +91.80.2852.8088 LOGO: http://www.cardiacscience.com/images/main_logo.gif

 

###